Telomir-1 reduces oxidative stress in human retinal cells, advancing potential AMD treatment

Telomir Pharmaceuticals, Inc.

Telomir-1 significantly reduced reactive oxygen species (ROS) elevation from copper and iron exposure in human retinal cell lines.
Compound showed strong ROS regulation at low concentrations, suggesting a regulatory effect beyond metal chelation.
Study targets age-related macular degeneration (AMD) and other retinal diseases linked to oxidative stress.
Company initiating AMD disease models to evaluate in vivo efficacy and support potential clinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.